Ulocuplumab with Low Dose Cytarabine in Acute Myeloid Leukemia

Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Walton, Sherri

    Trial Phone: 321.841.1907

  • IRB No: 17.013.02

    Protocol Abbrev: BMS CA212-016

    Principal Investigator: Daniel Ari Landau, MD

    Sub Investigators: Hajdenberg, Julio MD

    Phase: Drug: Phase I

    Age Group: Adult

    Secondary Protocol No: CA212016

    Treatment: Oncology: 1st line

    Applicable Disease Sites: Acute Myeloid Leukemia

    Therapies Involved: Ulocuplumab In Combination with Low Dose Cytarabine

    ClinicalTrials.gov ID: NCT02305563

  • Objective

    The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).

  • Key Eligibility

    Newly Diagnosed Acute Myeloid Leukemia (AML)
    Considered inappropriate for intensive remission induction therapy by an investigator
    Not eligible for stem cell transplantation